Cabozantinib
Ipsen
['thank you', 'cabozantinib']
 thank you for highlighting cabozantinib pure 2nd line study orr 30% across patients who failed first line combination regimen! important to move the field forward in io refractory patients . looking forward to randomized studies in this setting
Medical Oncologist - GU oncology; Chair Med Onc Dpmt @gustaveroussy ; Professor of medecine @UniversiteParisSaclay #kidneycancer #RCC views are mine